Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > TCRR TCR2 Therapeutics > Detailed Quotes

TCRR TCR2 Therapeutics

Watchlist
1.180
-0.090-7.09%
Close  12/08 16:00 ET
1.1800.0000.00%
Post Mkt Price 12/08 16:10 ET
High
1.300
Open
1.280
Turnover
618.36K
Low
1.140
Pre Close
1.270
Volume
513.42K
Market Cap
45.62M
P/E(TTM)
Loss
52wk High
5.200
Shares
38.66M
P/E(Static)
Loss
52wk Low
1.140
Float Cap
32.00M
Bid/Ask %
0.00%
Historical High
35.860
Shs Float
27.12M
Volume Ratio
1.63
Historical Low
1.140
Dividend TTM
--
Div Yield TTM
--
P/B
0.23
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.89%
Amplitude
12.60%
Avg Price
1.204
Lot Size
1
Float Cap
32.00M
Bid/Ask %
0.00%
Historical High
35.860
Shs Float
27.12M
Volume Ratio
1.63
Historical Low
1.140
Dividend TTM
--
P/B
0.23
Dividend LFY
--
Turnover Ratio
1.89%
Amplitude
12.60%
Avg Price
1.204
Lot Size
1
Price Forecast

News

Comment

Company Overview More
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
CEO: Dr. Garry E. Menzel, PhD
Market: NASDAQ
Listing Date: 02/14/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist